A Phase 1-2 Study of Etentamig Plus Iberdomide in People With Multiple Myeloma

Full Title

A Phase 1/2 Study of Etentamig in Combination with a CELMoD Agent for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma

Purpose

Researchers want to see if combining etentamig (ABBV-383) with iberdomide is a safe treatment for multiple myeloma. The people in this study have multiple myeloma that came back or keeps growing after treatment. The researchers will assess different doses of these drugs to find the best dose for patients.

Etentamig is a bispecific antibody. It binds to one protein on cancer cells and to another on immune cells called T cells. Etentamig may strengthen your immune system’s ability to fight cancer cells by activating your own cells to destroy your tumor. It is given intravenously (by vein).

Iberdomide is already used to treat multiple myeloma. It works against cancer by helping to change or control the function of the immune system. Iberdomide is taken orally (by mouth).

Contact

For more information about this study or to see if you can join, please call Dr. Neha Korde’s office at 646-608-3708.